25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Shield Therapeutics plc
Buy, Hold or Sell?

Let's analyze Shield Therapeutics plc together

I guess you are interested in Shield Therapeutics plc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Shield Therapeutics plc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Shield Therapeutics plc

I send you an email if I find something interesting about Shield Therapeutics plc.

1. Quick Overview

1.1. Quick analysis of Shield Therapeutics plc (30 sec.)










1.2. What can you expect buying and holding a share of Shield Therapeutics plc? (30 sec.)

How much money do you get?

How much money do you get?
p0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
p1.17
Expected worth in 1 year
p3.69
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
p2.52
Return On Investment
84.0%

For what price can you sell your share?

Current Price per Share
p3.00
Expected price per share
p2 - p3.4
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Shield Therapeutics plc (5 min.)




Live pricePrice per Share (EOD)
p3.00
Intrinsic Value Per Share
p-54.97 - p-38.75
Total Value Per Share
p-53.80 - p-37.58

2.2. Growth of Shield Therapeutics plc (5 min.)




Is Shield Therapeutics plc growing?

Current yearPrevious yearGrowGrow %
How rich?$11.7m$5.4m$6.3m54.0%

How much money is Shield Therapeutics plc making?

Current yearPrevious yearGrowGrow %
Making money-$26.7m-$40.4m$13.6m51.0%
Net Profit Margin-254.4%-905.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Shield Therapeutics plc (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Shield Therapeutics plc?

Welcome investor! Shield Therapeutics plc's management wants to use your money to grow the business. In return you get a share of Shield Therapeutics plc.

First you should know what it really means to hold a share of Shield Therapeutics plc. And how you can make/lose money.

Speculation

The Price per Share of Shield Therapeutics plc is p3. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Shield Therapeutics plc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Shield Therapeutics plc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is p1.17. Based on the TTM, the Book Value Change Per Share is p0.63 per quarter. Based on the YOY, the Book Value Change Per Share is p-3.52 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is p0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Shield Therapeutics plc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 p% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Share
Usd Eps-0.03-1.1%-0.03-1.1%-0.05-1.7%-0.03-0.8%-0.02-0.7%
Usd Book Value Change Per Share0.010.3%0.010.3%-0.05-1.5%-0.01-0.2%0.000.1%
Usd Dividend Per Share0.000.0%0.000.0%0.010.3%0.000.1%0.000.0%
Usd Total Gains Per Share0.010.3%0.010.3%-0.04-1.2%-0.01-0.2%0.000.1%
Usd Price Per Share0.09-0.09-0.09-0.78-0.80-
Price to Earnings Ratio-2.53--2.53--1.76--95.41--82.34-
Price-to-Total Gains Ratio10.64-10.64--2.54--102.34--130.04-
Price to Book Ratio5.74-5.74-13.13-21.46-17.86-
Price-to-Total Gains Ratio10.64-10.64--2.54--102.34--130.04-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.03876
Number of shares25799
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.01-0.01
Usd Total Gains Per Share0.01-0.01
Gains per Quarter (25799 shares)209.99-139.27
Gains per Year (25799 shares)839.96-557.08
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10840830199-756-567
2016801670397-1512-1124
3025202510596-2267-1681
4033603350795-3023-2238
5042004190993-3779-2795
60504050301192-4535-3352
70588058701391-5290-3909
80672067101590-6046-4466
90756075501788-6802-5023
100840083901987-7558-5580

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.010.00.00.0%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%2.03.00.040.0%3.07.00.030.0%3.07.00.030.0%
Dividend per Share0.00.01.00.0%1.00.02.033.3%1.00.04.020.0%1.00.09.010.0%1.00.09.010.0%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%2.03.00.040.0%3.07.00.030.0%3.07.00.030.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Shield Therapeutics plc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.6300.6300%-3.524+659%-0.567+190%0.117+440%
Book Value Per Share--1.1671.1670%0.537+117%2.389-51%2.116-45%
Current Ratio--2.2762.2760%0.949+140%2.437-7%2.695-16%
Debt To Asset Ratio--0.6920.6920%0.754-8%0.341+103%2.866-76%
Debt To Equity Ratio--2.2462.2460%3.067-27%1.120+101%0.585+284%
Dividend Per Share----0%0.745-100%0.149-100%0.075-100%
Eps---2.651-2.6510%-4.003+51%-1.940-27%-1.692-36%
Free Cash Flow Per Share---3.198-3.1980%-1.993-38%-1.547-52%-1.211-62%
Free Cash Flow To Equity Per Share--0.8040.8040%-1.231+253%-0.052+107%0.050+1508%
Gross Profit Margin--1.8111.8110%1.396+30%1.370+32%1.454+25%
Intrinsic Value_10Y_max---38.746--------
Intrinsic Value_10Y_min---54.971--------
Intrinsic Value_1Y_max---2.055--------
Intrinsic Value_1Y_min---3.179--------
Intrinsic Value_3Y_max---7.567--------
Intrinsic Value_3Y_min---11.626--------
Intrinsic Value_5Y_max---14.758--------
Intrinsic Value_5Y_min---22.282--------
Market Cap2346168000.000-123%5239775200.0005239775200.0000%5513494800.000-5%47040668400.000-89%48233303800.000-89%
Net Profit Margin---2.544-2.5440%-9.054+256%-7.364+189%-17.001+568%
Operating Margin---2.732-2.7320%-5.593+105%-6.784+148%-15.896+482%
Operating Ratio--3.7323.7320%6.755-45%7.879-53%13.060-71%
Pb Ratio2.570-123%5.7415.7410%13.126-56%21.456-73%17.861-68%
Pe Ratio-1.132+55%-2.528-2.5280%-1.761-30%-95.405+3675%-82.344+3158%
Price Per Share3.000-123%6.7006.7000%7.050-5%60.150-89%61.675-89%
Price To Free Cash Flow Ratio-0.938+55%-2.095-2.0950%-3.537+69%-162.458+7655%-108.803+5094%
Price To Total Gains Ratio4.762-123%10.63510.6350%-2.537+124%-102.339+1062%-130.045+1323%
Quick Ratio--2.0432.0430%0.617+231%1.927+6%2.310-12%
Return On Assets---0.700-0.7000%-1.832+162%-0.658-6%-2.517+260%
Return On Equity---2.271-2.2710%-7.452+228%-2.111-7%-1.139-50%
Total Gains Per Share--0.6300.6300%-2.779+541%-0.418+166%0.191+229%
Usd Book Value--11792532.34011792532.3400%5427043.416+117%24134880.678-51%21378114.824-45%
Usd Book Value Change Per Share--0.0080.0080%-0.046+659%-0.007+190%0.002+440%
Usd Book Value Per Share--0.0150.0150%0.007+117%0.031-51%0.027-45%
Usd Dividend Per Share----0%0.010-100%0.002-100%0.001-100%
Usd Eps---0.034-0.0340%-0.052+51%-0.025-27%-0.022-36%
Usd Free Cash Flow---32315080.519-32315080.5190%-20142161.136-38%-15626489.411-52%-12239380.114-62%
Usd Free Cash Flow Per Share---0.041-0.0410%-0.026-38%-0.020-52%-0.016-62%
Usd Free Cash Flow To Equity Per Share--0.0100.0100%-0.016+253%-0.001+107%0.001+1508%
Usd Market Cap30312490.560-123%67697895.58467697895.5840%71234352.816-5%607765435.728-89%623174285.096-89%
Usd Price Per Share0.039-123%0.0870.0870%0.091-5%0.777-89%0.797-89%
Usd Profit---26783489.266-26783489.2660%-40444323.552+51%-19598811.789-27%-17092464.239-36%
Usd Revenue--10526595.21210526595.2120%4467035.736+136%5523746.390+91%4068483.648+159%
Usd Total Gains Per Share--0.0080.0080%-0.036+541%-0.005+166%0.002+229%
 EOD+2 -6MRQTTM+0 -0YOY+27 -95Y+15 -2110Y+16 -20

3.3 Fundamental Score

Let's check the fundamental score of Shield Therapeutics plc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.132
Price to Book Ratio (EOD)Between0-12.570
Net Profit Margin (MRQ)Greater than0-2.544
Operating Margin (MRQ)Greater than0-2.732
Quick Ratio (MRQ)Greater than12.043
Current Ratio (MRQ)Greater than12.276
Debt to Asset Ratio (MRQ)Less than10.692
Debt to Equity Ratio (MRQ)Less than12.246
Return on Equity (MRQ)Greater than0.15-2.271
Return on Assets (MRQ)Greater than0.05-0.700
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Shield Therapeutics plc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.721
Ma 20Greater thanMa 504.166
Ma 50Greater thanMa 1004.308
Ma 100Greater thanMa 2003.328
OpenGreater thanClose2.900
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Shield Therapeutics plc

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

Fundamental data was last updated by Penke on 2024-10-26 00:27:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Shield Therapeutics plc earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare Shield Therapeutics plc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -254.4% means that -2.54 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Shield Therapeutics plc:

  • The MRQ is -254.4%. The company is making a huge loss. -2
  • The TTM is -254.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-254.4%TTM-254.4%0.0%
TTM-254.4%YOY-905.4%+651.0%
TTM-254.4%5Y-736.4%+482.0%
5Y-736.4%10Y-1,700.1%+963.7%
4.3.1.2. Return on Assets

Shows how efficient Shield Therapeutics plc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Shield Therapeutics plc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -70.0% Return on Assets means that Shield Therapeutics plc generated -0.70 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Shield Therapeutics plc:

  • The MRQ is -70.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -70.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-70.0%TTM-70.0%0.0%
TTM-70.0%YOY-183.2%+113.3%
TTM-70.0%5Y-65.8%-4.2%
5Y-65.8%10Y-251.7%+185.9%
4.3.1.3. Return on Equity

Shows how efficient Shield Therapeutics plc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Shield Therapeutics plc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -227.1% Return on Equity means Shield Therapeutics plc generated -2.27 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Shield Therapeutics plc:

  • The MRQ is -227.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -227.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-227.1%TTM-227.1%0.0%
TTM-227.1%YOY-745.2%+518.1%
TTM-227.1%5Y-211.1%-16.0%
5Y-211.1%10Y-113.9%-97.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Shield Therapeutics plc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Shield Therapeutics plc is operating .

  • Measures how much profit Shield Therapeutics plc makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Shield Therapeutics plc to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -273.2% means the company generated -2.73  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Shield Therapeutics plc:

  • The MRQ is -273.2%. The company is operating very inefficient. -2
  • The TTM is -273.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-273.2%TTM-273.2%0.0%
TTM-273.2%YOY-559.3%+286.2%
TTM-273.2%5Y-678.4%+405.3%
5Y-678.4%10Y-1,589.6%+911.2%
4.3.2.2. Operating Ratio

Measures how efficient Shield Therapeutics plc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 3.73 means that the operating costs are 3.73 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of Shield Therapeutics plc:

  • The MRQ is 3.732. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.732. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.732TTM3.7320.000
TTM3.732YOY6.755-3.023
TTM3.7325Y7.879-4.147
5Y7.87910Y13.060-5.181
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Shield Therapeutics plc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Shield Therapeutics plc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.28 means the company has 2.28 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of Shield Therapeutics plc:

  • The MRQ is 2.276. The company is able to pay all its short-term debts. +1
  • The TTM is 2.276. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.276TTM2.2760.000
TTM2.276YOY0.949+1.327
TTM2.2765Y2.437-0.161
5Y2.43710Y2.695-0.258
4.4.3.2. Quick Ratio

Measures if Shield Therapeutics plc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Shield Therapeutics plc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 2.04 means the company can pay off 2.04 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Shield Therapeutics plc:

  • The MRQ is 2.043. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.043. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.043TTM2.0430.000
TTM2.043YOY0.617+1.426
TTM2.0435Y1.927+0.116
5Y1.92710Y2.310-0.383
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Shield Therapeutics plc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Shield Therapeutics plc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Shield Therapeutics plc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.69 means that Shield Therapeutics plc assets are financed with 69.2% credit (debt) and the remaining percentage (100% - 69.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Shield Therapeutics plc:

  • The MRQ is 0.692. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.692. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.692TTM0.6920.000
TTM0.692YOY0.754-0.062
TTM0.6925Y0.341+0.351
5Y0.34110Y2.866-2.525
4.5.4.2. Debt to Equity Ratio

Measures if Shield Therapeutics plc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Shield Therapeutics plc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 224.6% means that company has 2.25 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Shield Therapeutics plc:

  • The MRQ is 2.246. The company is just not able to pay all its debts with equity.
  • The TTM is 2.246. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.246TTM2.2460.000
TTM2.246YOY3.067-0.821
TTM2.2465Y1.120+1.126
5Y1.12010Y0.585+0.535
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings Shield Therapeutics plc generates.

  • Above 15 is considered overpriced but always compare Shield Therapeutics plc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -2.53 means the investor is paying -2.53 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Shield Therapeutics plc:

  • The EOD is -1.132. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.528. Based on the earnings, the company is expensive. -2
  • The TTM is -2.528. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.132MRQ-2.528+1.396
MRQ-2.528TTM-2.5280.000
TTM-2.528YOY-1.761-0.766
TTM-2.5285Y-95.405+92.878
5Y-95.40510Y-82.344-13.061
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Shield Therapeutics plc:

  • The EOD is -0.938. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.095. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.095. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.938MRQ-2.095+1.157
MRQ-2.095TTM-2.0950.000
TTM-2.095YOY-3.537+1.442
TTM-2.0955Y-162.458+160.363
5Y-162.45810Y-108.803-53.655
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Shield Therapeutics plc is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Shield Therapeutics plc:

  • The EOD is 2.570. Based on the equity, the company is underpriced. +1
  • The MRQ is 5.741. Based on the equity, the company is overpriced. -1
  • The TTM is 5.741. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD2.570MRQ5.741-3.170
MRQ5.741TTM5.7410.000
TTM5.741YOY13.126-7.385
TTM5.7415Y21.456-15.715
5Y21.45610Y17.861+3.595
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Accumulated Other Comprehensive Income  5,341-1,2384,102108,050112,153162,850275,002-788,169-513,167
Net Interest Income  1,238-1,08415529,79929,954-4,25725,697-64,474-38,777



6.2. Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets38,280
Total Liabilities26,487
Total Stockholder Equity11,792
 As reported
Total Liabilities 26,487
Total Stockholder Equity+ 11,792
Total Assets = 38,280

Assets

Total Assets38,280
Total Current Assets24,524
Long-term Assets13,756
Total Current Assets
Cash And Cash Equivalents 10,941
Net Receivables 11,070
Inventory 2,513
Other Current Assets 0
Total Current Assets  (as reported)24,524
Total Current Assets  (calculated)24,524
+/-0
Long-term Assets
Property Plant Equipment 528
Intangible Assets 16,863
Long-term Assets Other -3,635
Long-term Assets  (as reported)13,756
Long-term Assets  (calculated)13,756
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities10,774
Long-term Liabilities15,713
Total Stockholder Equity11,792
Total Current Liabilities
Short-term Debt 168
Accounts payable 9,979
Other Current Liabilities 628
Total Current Liabilities  (as reported)10,774
Total Current Liabilities  (calculated)10,774
+/- 0
Long-term Liabilities
Long term Debt 19,836
Capital Lease Obligations Min Short Term Debt241
Long-term Liabilities  (as reported)15,713
Long-term Liabilities  (calculated)20,077
+/- 4,364
Total Stockholder Equity
Common Stock11,775
Retained Earnings -149,267
Accumulated Other Comprehensive Income -6,630
Other Stockholders Equity 155,914
Total Stockholder Equity (as reported)11,792
Total Stockholder Equity (calculated)11,792
+/-0
Other
Capital Stock15,011
Cash and Short Term Investments 10,941
Common Stock Shares Outstanding 722,540
Current Deferred Revenue0
Liabilities and Stockholders Equity 38,280
Net Debt 4,940
Net Invested Capital 34,869
Net Working Capital 17,528
Property Plant and Equipment Gross 1,198
Short Long Term Debt Total 15,881



6.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
> Total Assets 
2,043
1,004
2,860
52,384
44,970
43,381
36,319
32,528
44,413
22,074
38,280
38,28022,07444,41332,52836,31943,38144,97052,3842,8601,0042,043
   > Total Current Assets 
1,651
556
2,330
23,381
14,996
12,416
6,395
5,230
17,258
10,094
24,524
24,52410,09417,2585,2306,39512,41614,99623,3812,3305561,651
       Cash And Cash Equivalents 
1,550
477
725
20,978
13,299
9,776
4,141
2,940
12,117
2,821
10,941
10,9412,82112,1172,9404,1419,77613,29920,9787254771,550
       Net Receivables 
81
51
96
1,058
529
1,962
1,147
656
1,773
3,744
11,070
11,0703,7441,7736561,1471,9625291,058965181
       Other Current Assets 
0
79
1,605
1,985
1,572
2,531
159
255
1,732
2,072
0
02,0721,7322551592,5311,5721,9851,605790
   > Long-term Assets 
0
448
530
29,003
29,974
30,965
29,924
27,298
27,155
11,980
13,756
13,75611,98027,15527,29829,92430,96529,97429,0035304480
       Property Plant Equipment 
5
12
17
19
13
8
26
32
304
197
528
52819730432268131917125
       Intangible Assets 
387
436
513
28,984
29,961
30,957
29,898
27,266
26,851
11,783
16,863
16,86311,78326,85127,26629,89830,95729,96128,984513436387
       Other Assets 
0
0
0
2,524
5,370
7,942
8,961
8,434
9,529
0
0
009,5298,4348,9617,9425,3702,524000
> Total Liabilities 
8,048
19,288
21,503
3,988
3,763
2,951
4,174
2,252
3,380
16,647
26,487
26,48716,6473,3802,2524,1742,9513,7633,98821,50319,2888,048
   > Total Current Liabilities 
8,048
9,002
3,575
3,988
3,763
2,951
4,174
2,252
3,380
10,639
10,774
10,77410,6393,3802,2524,1742,9513,7633,9883,5759,0028,048
       Short-term Debt 
7,093
8,258
0
0
0
147
20
28
156
89
168
1688915628201470008,2587,093
       Short Long Term Debt 
7,093
8,258
0
0
0
0
0
0
0
0
0
0000000008,2587,093
       Accounts payable 
266
419
1,213
3,827
3,501
2,548
3,547
1,471
3,114
9,489
9,979
9,9799,4893,1141,4713,5472,5483,5013,8271,213419266
       Other Current Liabilities 
36
50
2,362
161
262
403
607
753
110
1,061
628
6281,0611107536074032621612,3625036
   > Long-term Liabilities 
0
10,286
17,928
1,490
1,802
22
3,567
1,499
1,467
6,008
15,713
15,7136,0081,4671,4993,567221,8021,49017,92810,2860
       Other Liabilities 
0
194
17,928
0
0
0
0
0
0
466
0
046600000017,9281940
       Deferred Long Term Liability 
0
0
0
2,524
5,370
7,942
8,961
8,434
9,529
0
0
009,5298,4348,9617,9425,3702,524000
> Total Stockholder Equity
-8,064
-20,030
-18,643
48,396
41,207
40,430
32,145
30,276
41,033
5,427
11,792
11,7925,42741,03330,27632,14540,43041,20748,396-18,643-20,030-8,064
   Common Stock
365
365
690
1,622
1,746
1,746
1,758
1,764
3,238
3,891
11,775
11,7753,8913,2381,7641,7581,7461,7461,622690365365
   Retained Earnings -149,267-146,638-106,595-88,251-86,392-78,048-77,267-62,380-47,652-23,006-10,792
   Accumulated Other Comprehensive Income 
0
0
-4
-10
-16
-21
69
53
1,449
3,553
-6,630
-6,6303,5531,4495369-21-16-10-400
   Capital Surplus 00000000000
   Treasury Stock00000000000



6.4. Balance Sheets

Currency in USD. All numbers in thousands.




6.5. Cash Flows

Currency in USD. All numbers in thousands.




6.6. Income Statements

Currency in USD. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue10,527
Cost of Revenue-8,148
Gross Profit2,3782,378
 
Operating Income (+$)
Gross Profit2,378
Operating Expense-31,132
Operating Income-28,754-28,754
 
Operating Expense (+$)
Research Development1,456
Selling General Administrative15,172
Selling And Marketing Expenses21,717
Operating Expense31,13238,345
 
Net Interest Income (+$)
Interest Income518
Interest Expense-1,257
Other Finance Cost-238
Net Interest Income-501
 
Pretax Income (+$)
Operating Income-28,754
Net Interest Income-501
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-26,045-31,464
EBIT - interestExpense = -30,011
-26,045
-25,527
Interest Expense1,257
Earnings Before Interest and Taxes (EBIT)-28,754-24,788
Earnings Before Interest and Taxes (EBITDA)-27,893
 
After tax Income (+$)
Income Before Tax-26,045
Tax Provision-918
Net Income From Continuing Ops-33,293-26,963
Net Income-26,783
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses39,281
Total Other Income/Expenses Net2,709501
 

Technical Analysis of Shield Therapeutics plc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Shield Therapeutics plc. The general trend of Shield Therapeutics plc is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Shield Therapeutics plc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Shield Therapeutics plc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.2 < 3.4 < 3.4.

The bearish price targets are: 2.5 > 2.4 > 2.

Tweet this
Shield Therapeutics plc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Shield Therapeutics plc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shield Therapeutics plc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Shield Therapeutics plc. The current macd is -0.25249418.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Shield Therapeutics plc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Shield Therapeutics plc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Shield Therapeutics plc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Shield Therapeutics plc Daily Moving Average Convergence/Divergence (MACD) ChartShield Therapeutics plc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Shield Therapeutics plc. The current adx is 23.79.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Shield Therapeutics plc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Shield Therapeutics plc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Shield Therapeutics plc. The current sar is 4.57103783.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Shield Therapeutics plc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Shield Therapeutics plc. The current rsi is 29.72. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 2/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending up: The RSI is trending up. +1
Shield Therapeutics plc Daily Relative Strength Index (RSI) ChartShield Therapeutics plc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Shield Therapeutics plc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Shield Therapeutics plc price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Shield Therapeutics plc Daily Stochastic Oscillator ChartShield Therapeutics plc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Shield Therapeutics plc. The current cci is -207.13966553.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Shield Therapeutics plc Daily Commodity Channel Index (CCI) ChartShield Therapeutics plc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Shield Therapeutics plc. The current cmo is -57.32930535.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Shield Therapeutics plc Daily Chande Momentum Oscillator (CMO) ChartShield Therapeutics plc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Shield Therapeutics plc. The current willr is -91.38381201.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Shield Therapeutics plc Daily Williams %R ChartShield Therapeutics plc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Shield Therapeutics plc.

Shield Therapeutics plc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Shield Therapeutics plc. The current atr is 0.39151757.

Shield Therapeutics plc Daily Average True Range (ATR) ChartShield Therapeutics plc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Shield Therapeutics plc. The current obv is -160,013,616.

Shield Therapeutics plc Daily On-Balance Volume (OBV) ChartShield Therapeutics plc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Shield Therapeutics plc. The current mfi is 14.93.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Shield Therapeutics plc Daily Money Flow Index (MFI) ChartShield Therapeutics plc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Shield Therapeutics plc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-06-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-06-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-07-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-01ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-08-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-09ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-23BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-10-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-29STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Shield Therapeutics plc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Shield Therapeutics plc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.721
Ma 20Greater thanMa 504.166
Ma 50Greater thanMa 1004.308
Ma 100Greater thanMa 2003.328
OpenGreater thanClose2.900
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Shield Therapeutics plc with someone you think should read this too:
  • Are you bullish or bearish on Shield Therapeutics plc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Shield Therapeutics plc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Shield Therapeutics plc

I send you an email if I find something interesting about Shield Therapeutics plc.


Comments

How you think about this?

Leave a comment

Stay informed about Shield Therapeutics plc.

Receive notifications about Shield Therapeutics plc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.